Pravin U. Dugel, MD, Ocular’s Executive Chairman, President and CEO, will provide an update regarding the enrollment status of SOL-R, the Company’s second registrational trial of AXPAXLI™ for the ...

Updates on commercial insights and readiness plans for sozinibercept in wet AMDOpthea management to present in New York City on Tuesday, January ...

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal ...

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...

ASD Specialty Healthcare LLC, trading as Besse Medical, has reached a $1.67 million settlement to resolve allegations of ...

Reducing the risk of eye diseases involves a combination of lifestyle changes, protective measures and regular eye care ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...